Iris Submits 510(k) for Prostate Cancer Test
Iris Molecular Diagnostics, a subsidiary of Iris International Inc, has filed a 510(k) application with the FDA for its ultra-sensitive Prostate-Specific Antigen (PSA) test.
Read MoreSearch Results for: prostate cancer
Testing/Diagnostics
Anti-Prostate Specific Antigen AVAILABLE CONCENTRATED AND AS A REAGENT BioGenex, San Ramon, Calif, polyclonal anti-Prostate Specific Antigen antibody is designed for the specific localization of Prostate Specific Antigen (PSA) in fo
Read MoreNew Biomarker for Early Detection of Prostate Cancer Identified
Scientists at a Maryland-based pharmaceutical company have preliminary evidence showing that a protein in the blood may prove to be a biomarker that is more sensitive and specific than current methods of early detection for prostate cancer.
Read MoreThe Latest in the Fight Against Prostate Cancer
Though National Cancer Institute (NCI) statistics reveal that prostate cancer is the most frequently diagnosed cancer in the United States, we know less about its causes and risks than we do about almost every other major
Read More